Clinical Trials
29 trialsMetronomic Oral Paclitaxel Monotherapy and Combined Immunotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose Exploration and Expansion Trial
Zhejiang Cancer Hospital
PONTIAC
MedSIR
Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OASIS
UNICANCER
ESPERO
Seoul National University Hospital
CORIN-PYRA
RenJi Hospital
ITHRAN
RenJi Hospital
HERMIONE-7
University of Milano Bicocca
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
Fudan University
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency
Seoul National University Hospital
Post-CDK
Seoul National University Hospital
Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer
Affiliated Cancer Hospital of Shantou University Medical College
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer
Fudan University
Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)
The First Affiliated Hospital with Nanjing Medical University
COMETABreast
Spanish Breast Cancer Research Group
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
Beijing GoBroad Hospital
A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer
Peking University Cancer Hospital & Institute
Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
The First Affiliated Hospital with Nanjing Medical University
CAILA
MedSIR
VEX
European Institute of Oncology
PANGEA
Spanish Breast Cancer Research Group
OPHELIA
MedSIR
Dalpiciclib Plus Letrozole and Capecitabine
Fujian Medical University Union Hospital
The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Metronomic PLD in Patients With Primary Endocrine Resistant ABC
Fudan University
Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer
Fujian Medical University Union Hospital
plasmaMATCH
Institute of Cancer Research, United Kingdom
Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer
Sun Yat-sen University